Entering text into the input field will update the search result below

Novartis malaria drug candidate delivers encouraging results

Jul. 31, 2014 1:04 PM ETNovartis AG (NVS) StockNVSBy: Douglas W. House, SA News Editor
  • In a just-published article detailing clinical trial results for Novartis' (NVS -1.2%) antimalarial drug candidate, KAE609 (cipargamin), the parasite was cleared in adult patients in a median time of only 12 hours, including patients with resistant infections.
  • KAE609 is the first compound is the spiroindolone class of treatment. It inhibits the P-type cation-transporter ATPase4 (PfATP4), which regulates sodium concentration in plasmodium. The inhibition raises the level of sodium in the parasite to a fatal level.
  • The preliminary results are welcome news to malaria researchers because the parasites are developing resistance to artemisinin, the current standard of care.

Recommended For You

More Trending News

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG